Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol
Investigating the Secondhand Effects of Hookah Smoking and Vaping
1 other identifier
interventional
12
1 country
1
Brief Summary
In the United States, secondhand smoke is the third leading preventable cause of death. Flavored hookah (waterpipe) tobacco smoking, a highly social activity common in hookah bars, is a key source of SHS exposure. While smoke-free air laws have decreased exposure to secondhand smoke, the majority of laws do not include hookah smoking. Thus, as a social outlet for youth and young adults, hookah smoke exposure may harm non-smokers, including women of reproductive age or pregnant, hookah bar workers, children, and individuals with heart and lung disease. While more is known on the acute effects of active hookah smoking and the literature is emerging on active e-hookah vaping, little is known about the acute vascular effects of secondhand exposure to hookah smoke and aerosol. The study aims to examine the acute effects of secondhand exposure of hookah smoke and aerosol on endothelial and vascular function. Eligible volunteers will be invited to participate in a total of 3 study visits (2-3 hours each): e-hookah aerosol exposure, charcoal-heated hookah smoke exposure and smoke-free room air. Non-invasive blood pressure and blood flow measurements will be taken before and after the exposure sessions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 3, 2020
CompletedFirst Posted
Study publicly available on registry
December 10, 2020
CompletedStudy Start
First participant enrolled
June 25, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 15, 2027
April 22, 2026
April 1, 2026
5.5 years
December 3, 2020
April 17, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Flow-Mediated Dilation (FMD)
Using ultrasound, FMD of the brachial artery induced by reactive hyperemia, will be used to measure endothelium-dependent vasodilator function. Baseline diameter and velocity will be recorded for 45 seconds and resumed 30 seconds before cuff deflation and continuously for 2 minutes after deflation to obtain true peak vasodilatory response.
Pre- and post- the 60-minute exposure sessions
Arterial stiffness
Using applanation tonometry, pulse wave velocity will be used to measure cebtral arterial stiffness.
Pre- and post- the 60-minute exposure sessions
Study Arms (3)
Exposure to Combustible Hookah Smoke
EXPERIMENTALParticipants will be exposed to combustible hookah smoke. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
Exposure to Electronic Hookah Aerosol
EXPERIMENTALParticipants will be exposed to electronic hookah aerosol. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
Exposure to Clean Air
EXPERIMENTALParticipants will be exposed to Clean Room Air. To mitigate the impact of carryover effects, the exposure sessions will be separated by a minimum of 7-days.
Interventions
Exposure to combustible hookah smoke for a duration of 60 minutes.
Exposure to electronic hookah aerosol for a duration of 60 minutes.
Eligibility Criteria
You may qualify if:
- years old
- Never a smoker: do not use any tobacco products or nicotine delivery systems, including cigarettes, cigars (traditional and filtered), cigarillos, hookah, smokeless tobacco (i.e., loose snus, moist snuff, dip, spit, or chewing tobacco), pipe tobacco, snus pouches, dissolvable tobacco or vaping.
- no evidence of cardiopulmonary disease by history/physical
- blood pressure (BP) \< 140/90 mmHg
- resting heart rate (HR) \< 100 bpm
- BMI \>18 or \< 30kg•m2
- no prescription medication
- No exposure to environmental tobacco smoke for at least one week prior to the study date.
You may not qualify if:
- exhaled carbon monoxide \>6 ppm
- (+) pregnancy test
- other conditions deemed unsafe to participate, such as breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of California, Los Angeles
Los Angeles, California, 90095-8361, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 3, 2020
First Posted
December 10, 2020
Study Start
June 25, 2021
Primary Completion (Estimated)
December 15, 2026
Study Completion (Estimated)
April 15, 2027
Last Updated
April 22, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share